This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a research study to investigate a new dosing regimen of erlotinib in patients with glioblastoma multiforme, a type of brain tumor, who have failed first line therapy.
Showing the most recent 10 out of 782 publications